Fig. 1From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesWaterfall plot of maximal responses in evaluable patients (n = 28 patients who were imaged at progression, *Expansion GIST patient). [GIST = gastrointestinal stromal tumor; RCC = renal cell carcinoma; NSCLC = non-small cell lung cancer]Back to article page